The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
• HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitop...
Ausführliche Beschreibung
Autor*in: |
Shibata, Takeo [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2019 |
---|
Schlagwörter: |
---|
Umfang: |
9 |
---|
Übergeordnetes Werk: |
Enthalten in: Using regression analysis to predict the future energy consumption of a supermarket in the UK - Braun, M.R. ELSEVIER, 2014, Amsterdam [u.a.] |
---|---|
Übergeordnetes Werk: |
volume:78 ; year:2019 ; pages:8-16 ; extent:9 |
Links: |
---|
DOI / URN: |
10.1016/j.ctrv.2019.07.001 |
---|
Katalog-ID: |
ELV047699531 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV047699531 | ||
003 | DE-627 | ||
005 | 20230624140821.0 | ||
007 | cr uuu---uuuuu | ||
008 | 191022s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ctrv.2019.07.001 |2 doi | |
028 | 5 | 2 | |a GBV00000000000726.pica |
035 | |a (DE-627)ELV047699531 | ||
035 | |a (ELSEVIER)S0305-7372(19)30084-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 620 |q VZ |
082 | 0 | 4 | |a 150 |a 300 |q VZ |
084 | |a 77.52 |2 bkl | ||
100 | 1 | |a Shibata, Takeo |e verfasserin |4 aut | |
245 | 1 | 4 | |a The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer |
264 | 1 | |c 2019 | |
300 | |a 9 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a • HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination. | ||
650 | 7 | |a Human papillomavirus |2 Elsevier | |
650 | 7 | |a Therapeutic vaccine |2 Elsevier | |
650 | 7 | |a Immunotherapy |2 Elsevier | |
650 | 7 | |a Checkpoint blockade |2 Elsevier | |
650 | 7 | |a Cervical cancer |2 Elsevier | |
700 | 1 | |a Lieblong, Benjamin J. |4 oth | |
700 | 1 | |a Sasagawa, Toshiyuki |4 oth | |
700 | 1 | |a Nakagawa, Mayumi |4 oth | |
773 | 0 | 8 | |i Enthalten in |n Elsevier |a Braun, M.R. ELSEVIER |t Using regression analysis to predict the future energy consumption of a supermarket in the UK |d 2014 |g Amsterdam [u.a.] |w (DE-627)ELV01225004X |
773 | 1 | 8 | |g volume:78 |g year:2019 |g pages:8-16 |g extent:9 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.ctrv.2019.07.001 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
936 | b | k | |a 77.52 |j Differentielle Psychologie |q VZ |
951 | |a AR | ||
952 | |d 78 |j 2019 |h 8-16 |g 9 |
author_variant |
t s ts |
---|---|
matchkey_str |
shibatatakeolieblongbenjaminjsasagawatos:2019----:hpoiefobnncnevciencekonbokdfrr |
hierarchy_sort_str |
2019 |
bklnumber |
77.52 |
publishDate |
2019 |
allfields |
10.1016/j.ctrv.2019.07.001 doi GBV00000000000726.pica (DE-627)ELV047699531 (ELSEVIER)S0305-7372(19)30084-2 DE-627 ger DE-627 rakwb eng 620 VZ 150 300 VZ 77.52 bkl Shibata, Takeo verfasserin aut The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer Elsevier Lieblong, Benjamin J. oth Sasagawa, Toshiyuki oth Nakagawa, Mayumi oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:78 year:2019 pages:8-16 extent:9 https://doi.org/10.1016/j.ctrv.2019.07.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 78 2019 8-16 9 |
spelling |
10.1016/j.ctrv.2019.07.001 doi GBV00000000000726.pica (DE-627)ELV047699531 (ELSEVIER)S0305-7372(19)30084-2 DE-627 ger DE-627 rakwb eng 620 VZ 150 300 VZ 77.52 bkl Shibata, Takeo verfasserin aut The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer Elsevier Lieblong, Benjamin J. oth Sasagawa, Toshiyuki oth Nakagawa, Mayumi oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:78 year:2019 pages:8-16 extent:9 https://doi.org/10.1016/j.ctrv.2019.07.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 78 2019 8-16 9 |
allfields_unstemmed |
10.1016/j.ctrv.2019.07.001 doi GBV00000000000726.pica (DE-627)ELV047699531 (ELSEVIER)S0305-7372(19)30084-2 DE-627 ger DE-627 rakwb eng 620 VZ 150 300 VZ 77.52 bkl Shibata, Takeo verfasserin aut The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer Elsevier Lieblong, Benjamin J. oth Sasagawa, Toshiyuki oth Nakagawa, Mayumi oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:78 year:2019 pages:8-16 extent:9 https://doi.org/10.1016/j.ctrv.2019.07.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 78 2019 8-16 9 |
allfieldsGer |
10.1016/j.ctrv.2019.07.001 doi GBV00000000000726.pica (DE-627)ELV047699531 (ELSEVIER)S0305-7372(19)30084-2 DE-627 ger DE-627 rakwb eng 620 VZ 150 300 VZ 77.52 bkl Shibata, Takeo verfasserin aut The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer Elsevier Lieblong, Benjamin J. oth Sasagawa, Toshiyuki oth Nakagawa, Mayumi oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:78 year:2019 pages:8-16 extent:9 https://doi.org/10.1016/j.ctrv.2019.07.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 78 2019 8-16 9 |
allfieldsSound |
10.1016/j.ctrv.2019.07.001 doi GBV00000000000726.pica (DE-627)ELV047699531 (ELSEVIER)S0305-7372(19)30084-2 DE-627 ger DE-627 rakwb eng 620 VZ 150 300 VZ 77.52 bkl Shibata, Takeo verfasserin aut The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer 2019 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination. Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer Elsevier Lieblong, Benjamin J. oth Sasagawa, Toshiyuki oth Nakagawa, Mayumi oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:78 year:2019 pages:8-16 extent:9 https://doi.org/10.1016/j.ctrv.2019.07.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 78 2019 8-16 9 |
language |
English |
source |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:78 year:2019 pages:8-16 extent:9 |
sourceStr |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:78 year:2019 pages:8-16 extent:9 |
format_phy_str_mv |
Article |
bklname |
Differentielle Psychologie |
institution |
findex.gbv.de |
topic_facet |
Human papillomavirus Therapeutic vaccine Immunotherapy Checkpoint blockade Cervical cancer |
dewey-raw |
620 |
isfreeaccess_bool |
false |
container_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
authorswithroles_txt_mv |
Shibata, Takeo @@aut@@ Lieblong, Benjamin J. @@oth@@ Sasagawa, Toshiyuki @@oth@@ Nakagawa, Mayumi @@oth@@ |
publishDateDaySort_date |
2019-01-01T00:00:00Z |
hierarchy_top_id |
ELV01225004X |
dewey-sort |
3620 |
id |
ELV047699531 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047699531</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624140821.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191022s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2019.07.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000726.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047699531</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(19)30084-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shibata, Takeo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Human papillomavirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapeutic vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Checkpoint blockade</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cervical cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lieblong, Benjamin J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sasagawa, Toshiyuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakagawa, Mayumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:78</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:8-16</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2019.07.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">78</subfield><subfield code="j">2019</subfield><subfield code="h">8-16</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
author |
Shibata, Takeo |
spellingShingle |
Shibata, Takeo ddc 620 ddc 150 bkl 77.52 Elsevier Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer |
authorStr |
Shibata, Takeo |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV01225004X |
format |
electronic Article |
dewey-ones |
620 - Engineering & allied operations 150 - Psychology 300 - Social sciences |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
620 VZ 150 300 VZ 77.52 bkl The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer Elsevier |
topic |
ddc 620 ddc 150 bkl 77.52 Elsevier Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer |
topic_unstemmed |
ddc 620 ddc 150 bkl 77.52 Elsevier Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer |
topic_browse |
ddc 620 ddc 150 bkl 77.52 Elsevier Human papillomavirus Elsevier Therapeutic vaccine Elsevier Immunotherapy Elsevier Checkpoint blockade Elsevier Cervical cancer |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
b j l bj bjl t s ts m n mn |
hierarchy_parent_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
hierarchy_parent_id |
ELV01225004X |
dewey-tens |
620 - Engineering 150 - Psychology 300 - Social sciences, sociology & anthropology |
hierarchy_top_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV01225004X |
title |
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer |
ctrlnum |
(DE-627)ELV047699531 (ELSEVIER)S0305-7372(19)30084-2 |
title_full |
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer |
author_sort |
Shibata, Takeo |
journal |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
journalStr |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology 100 - Philosophy & psychology 300 - Social sciences |
recordtype |
marc |
publishDateSort |
2019 |
contenttype_str_mv |
zzz |
container_start_page |
8 |
author_browse |
Shibata, Takeo |
container_volume |
78 |
physical |
9 |
class |
620 VZ 150 300 VZ 77.52 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Shibata, Takeo |
doi_str_mv |
10.1016/j.ctrv.2019.07.001 |
dewey-full |
620 150 300 |
title_sort |
promise of combining cancer vaccine and checkpoint blockade for treating hpv-related cancer |
title_auth |
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer |
abstract |
• HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination. |
abstractGer |
• HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination. |
abstract_unstemmed |
• HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
title_short |
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer |
url |
https://doi.org/10.1016/j.ctrv.2019.07.001 |
remote_bool |
true |
author2 |
Lieblong, Benjamin J. Sasagawa, Toshiyuki Nakagawa, Mayumi |
author2Str |
Lieblong, Benjamin J. Sasagawa, Toshiyuki Nakagawa, Mayumi |
ppnlink |
ELV01225004X |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth |
doi_str |
10.1016/j.ctrv.2019.07.001 |
up_date |
2024-07-06T16:51:55.811Z |
_version_ |
1803849266167283712 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047699531</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624140821.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191022s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2019.07.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000726.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047699531</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(19)30084-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shibata, Takeo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• HPV have ingenious immune suppressive mechanisms. • Checkpoint inhibitors have little efficacy against HPV-associated cancers. • HPV therapeutic vaccines have little efficacy against HPV-associated cancers. • However, combining these two therapeutic modalities is starting to show promise. • Epitope spreading may play a critical role mechanistically in this combination.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Human papillomavirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapeutic vaccine</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Checkpoint blockade</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cervical cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lieblong, Benjamin J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sasagawa, Toshiyuki</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakagawa, Mayumi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:78</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:8-16</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2019.07.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">78</subfield><subfield code="j">2019</subfield><subfield code="h">8-16</subfield><subfield code="g">9</subfield></datafield></record></collection>
|
score |
7.3986187 |